Nuance Investments LLC Reduces Stock Position in Agilent Technologies, Inc. $A

Key Points

• Nuance Investments LLC reduced its Agilent Technologies position by 59.8% in the second quarter, selling 19,686 shares and retaining 13,235 shares valued at approximately $1.76 million.
• Several major institutions increased their holdings, including Bank of New York Mellon, AQR Capital Management, Ameriprise Financial and Deutsche Bank, signaling continued institutional interest.
• Analysts maintain a “Moderate Buy” consensus with an average price target of $160.24. Agilent recently beat quarterly earnings and revenue expectations, reporting $1.49 in EPS and $1.83 billion in revenue.

Nuance Investments LLC cut its holdings in Agilent Technologies, Inc. (NYSE:A - Free Report) by 59.8% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 13,235 shares of the medical research company's stock after selling 19,686 shares during the quarter. Nuance Investments LLC's holdings in Agilent Technologies were worth $1,758,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors have also added to or reduced their stakes in A. Norges Bank bought a new stake in shares of Agilent Technologies during the 4th quarter valued at about $549,158,000. Bank of New York Mellon Corp grew its stake in shares of Agilent Technologies by 87.4% in the 2nd quarter. Bank of New York Mellon Corp now owns 5,233,964 shares of the medical research company's stock worth $695,227,000 after buying an additional 2,440,360 shares during the last quarter. AQR Capital Management LLC grew its stake in shares of Agilent Technologies by 424.1% in the second quarter. AQR Capital Management LLC now owns 2,041,826 shares of the medical research company's stock worth $240,956,000 after acquiring an additional 1,652,244 shares during the last quarter. Ameriprise Financial Inc. grew its position in Agilent Technologies by 132.2% during the 2nd quarter. Ameriprise Financial Inc. now owns 2,354,111 shares of the medical research company's stock valued at $277,807,000 after purchasing an additional 1,340,161 shares during the last quarter. Finally, Deutsche Bank AG increased its position in shares of Agilent Technologies by 17.1% during the second quarter. Deutsche Bank AG now owns 7,008,634 shares of the medical research company's stock valued at $930,957,000 after acquiring an additional 1,024,516 shares in the last quarter.

Wall Street Analysts Forecast Growth

Several equities research analysts recently commented on the company. TD Cowen lifted their price objective on Agilent Technologies from $147.00 to $155.00 and gave the stock a "buy" rating in a report on Thursday, May 28th. Barclays upped their price objective on Agilent Technologies from $145.00 to $150.00 and gave the stock an "overweight" rating in a research note on Wednesday, June 24th. Piper Sandler started coverage on shares of Agilent Technologies in a research note on Thursday, June 11th. They set a "neutral" rating and a $150.00 target price on the stock. Robert W. Baird upped their price objective on Agilent Technologies from $155.00 to $156.00 and gave the stock an "outperform" rating in a research note on Tuesday, May 26th. Finally, Wells Fargo & Company cut their target price on shares of Agilent Technologies from $165.00 to $160.00 and set an "overweight" rating for the company in a research note on Thursday, May 28th. Two research analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating and four have given a Hold rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $160.24.

Agilent Technologies Stock Performance

A stock opened at $148.65 on Tuesday. The company has a debt-to-equity ratio of 0.43, a current ratio of 2.10 and a quick ratio of 1.62. The business has a 50-day moving average price of $135.70 and a 200 day moving average price of $125.58. Agilent Technologies, Inc. has a 1-year low of $108.35 and a 1-year high of $160.27. The company has a market capitalization of $41.98 billion, a P/E ratio of 29.85, a PEG ratio of 2.63 and a beta of 1.25.

Agilent Technologies (NYSE:A - Get Free Report) last issued its quarterly earnings data on Wednesday, May 27th. The medical research company reported $1.49 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.41 by $0.08. The company had revenue of $1.83 billion for the quarter, compared to analyst estimates of $1.80 billion. Agilent Technologies had a net margin of 19.55% and a return on equity of 24.33%. Agilent Technologies's revenue was up 10.0% compared to the same quarter last year. During the same period last year, the company posted $1.31 earnings per share. Agilent Technologies has set its FY 2026 guidance at 6.000-6.100 EPS and its Q3 2026 guidance at 1.480-1.500 EPS. As a group, equities research analysts forecast that Agilent Technologies, Inc. will post 6.03 EPS for the current fiscal year.

Agilent Technologies Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Wednesday, July 22nd. Stockholders of record on Tuesday, June 30th were issued a $0.255 dividend. This represents a $1.02 dividend on an annualized basis and a dividend yield of 0.7%. The ex-dividend date was Tuesday, June 30th. Agilent Technologies's dividend payout ratio (DPR) is currently 20.48%.

About Agilent Technologies

Agilent Technologies is a global provider of scientific instrumentation, consumables, software and services for laboratories across the life sciences, diagnostics and applied chemical markets. The company's product portfolio includes analytical instruments such as liquid and gas chromatographs, mass spectrometers, spectroscopy systems, and laboratory automation solutions, together with reagents, supplies and informatics tools that support measurement, testing and data analysis workflows. Agilent also offers instrument maintenance, qualification and laboratory services designed to help customers improve productivity and comply with regulatory requirements.

Founded as a corporate spin-off from Hewlett‑Packard in 1999, Agilent has evolved through a combination of strategic restructuring and acquisitions to concentrate on life sciences, diagnostics and applied laboratories.

Want to see what other hedge funds are holding A? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Agilent Technologies, Inc. (NYSE:A - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source